Literature DB >> 9031903

Spontaneous ascitic infection in different cirrhotic groups: prevalence, risk factors and the efficacy of cefotaxime therapy.

S Kaymakoglu1, H Eraksoy, A Okten, K Demir, S Calangu, Y Cakaloglu, G Boztas, F Besisik.   

Abstract

OBJECTIVE: To investigate the prevalence of spontaneous ascitic infection (SAI) in different cirrhotic groups, the risk factors for development of SAI, and the efficacy of cefotaxime therapy.
DESIGN: A prospective study.
SETTING: In-patient clinic of a university hospital. PATIENTS: Eighty cirrhotic patients with ascites were assigned to four groups: hepatitis B or D virus-related 34, alcoholic 18, hepatitis C virus-related 14, miscellaneous 14.
INTERVENTIONS: Paracentesis was performed on 80 patients during 92 consecutive hospitalizations. Ascitic fluid was cultured by the method of bedside inoculation of blood culture bottles with ascites. The patients with SAI were treated with cefotaxime (2 g, three times daily, intravenously) for 5 days. MAIN OUTCOME MEASURES: Frequency of SAI in cirrhotic groups; clinical, bacteriological and biochemical findings of SAI; rate of recovery-from infection.
RESULTS: Twenty SAI episodes (22%) were found in 16 patients; 8 episodes were spontaneous bacterial peritonitis, 2 bacterascites, and 10 culture-negative neutrocytic ascites. SAI occurred more frequently in patients with hepatitis B or D virus-related liver cirrhosis (32%) than in the alcoholic (6%, P < 0.05), hepatitis C virus-related (14%) or miscellaneous (14%) cirrhotic groups in multivariate analysis, independent predictive factors associated with the development of SAI are chronic hepatitis B virus infection, ascitic fluid total protein and serum bilirubin. Escherichia coli was obtained in 5 of 10 positive ascitic fluid cultures. Cure of the infection was achieved in 95% of episodes. Hospitalization mortality rate in infected patients was 20%.
CONCLUSION: Spontaneous ascitic infection occurs in approximately 20% of cirrhotic patients hospitalized with ascites. The patients with low ascitic protein concentration, high serum bilirubin level or hepatitis B virus cirrhosis are more predisposed to SAI. Cefotaxime may be an effective first-choice antibiotic for ascitic fluid infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9031903     DOI: 10.1097/00042737-199701000-00017

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  [Spontaneous bacterial peritonitis].

Authors:  J Zundler; J C Bode
Journal:  Med Klin (Munich)       Date:  1998-10-15

2.  A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis.

Authors:  Tolga Yakar; Mustafa Güçlü; Ender Serin; Hikmet Alişkan; Erdamar Husamettin
Journal:  Dig Dis Sci       Date:  2009-05-08       Impact factor: 3.199

Review 3.  Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  Norberto C Chavez-Tapia; Karla Soares-Weiser; Mayer Brezis; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

4.  Spontaneous bacterial peritonitis in patients with hepatitis B virus-related liver cirrhosis: community-acquired versus nosocomial.

Authors:  Seung Up Kim; Young Eun Chon; Chun Kyon Lee; Jun Yong Park; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sinyoung Kim; Kyu Sik Jung; Sang Hoon Ahn
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

5.  Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis.

Authors:  Bledar Kraja; Marsela Sina; Iris Mone; Fatjona Pupuleku; Adriana Babameto; Skerdi Prifti; Genc Burazeri
Journal:  Gastroenterol Res Pract       Date:  2012-02-22       Impact factor: 2.260

6.  Culture-Positive Spontaneous Ascitic Infection in Patients with Acute Decompensated Cirrhosis: Multidrug-Resistant Pathogens and Antibiotic Strategies.

Authors:  Jing Liu; Yanhang Gao; Xianbo Wang; Zhiping Qian; Jinjun Chen; Yan Huang; Zhongji Meng; Xiaobo Lu; Guohong Deng; Feng Liu; Zhiguo Zhang; Hai Li; Xin Zheng
Journal:  Yonsei Med J       Date:  2020-02       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.